(Q46425753)

22 December 2017

title

Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancer (English)

1 reference

22 December 2017

1 reference

1 reference

Carroll P

1

1 reference

22 December 2017

Coley C

2

1 reference

22 December 2017

McLeod D

3

1 reference

22 December 2017

Schellhammer P

4

1 reference

22 December 2017

Sweat G

5

1 reference

22 December 2017

Wasson J

6

1 reference

22 December 2017

Zietman A

7

1 reference

22 December 2017

Thompson I

8

1 reference

22 December 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

22 December 2017

published in

Urology

1 reference

22 December 2017

volume

57

1 reference

22 December 2017

page(s)

217-224

1 reference

22 December 2017

issue

2

1 reference

22 December 2017

cites work

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Prostate cancer: screening, diagnosis, and management

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Screening for prostate cancer with prostate-specific antigen. An examination of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Correlation of pathologic findings with progression after radical retropubic prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Results of conservative management of clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Re: Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Prostate-specific antigen levels from completely sectioned, clinically benign, whole prostates

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

The definition and preoperative prediction of clinically insignificant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

The role of increasing detection in the rising incidence of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Prostatic Carcinoma: Incidence and Location of Unsuspected Lymphatic Metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Longitudinal screening for prostate cancer with prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Defining clinically significant prostate cancer: pathologic criteria versus outcomes data

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part II: Early detection strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Prostate-specific antigen and digital rectal examination in screening for prostate cancer: a community-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Stud

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

The effects of ejaculation on serum prostate-specific antigen (PSA)

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Prostate-specific antigen: current status

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Prostate-specific antigen as a screening test for prostate cancer. The United States experience

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Age-specific reference ranges for serum prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Risk factors for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Epidemiologic evidence regarding predisposing factors to prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Estimating treatment benefits for the elderly: the effect of competing risks

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Mendelian inheritance of familial prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Familial aspects of prostate cancer: a case control study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Familial patterns of prostate cancer: a case-control analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Family history and the risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Socioeconomic factors and cancer incidence among blacks and whites

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Cancer statistics for African Americans

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Low-grade, latent prostate cancer volume: predictor of clinical cancer incidence?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Prostatic cancer: mortality and incidence rates by race and social class

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900993-6

7 January 2021

10.1016/S0090-4295(00)00993-6

Identifiers

DOI

1 reference

22 December 2017

PubMed ID

11182324

1 reference

22 December 2017